TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: PaO2 and PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of post-procedural myocardial necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of post-procedural myocardial infarction (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Size of bone tunnels on femoral side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-HDL cholesterol decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: self-monitoring blood glucose improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Satisfaction with work
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in pre-stroke earnings
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Cerebral glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of low cerebral glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pelvic recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: global symptom and endoscopic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satiation scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: gastric tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: plasma gut hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Laparoscopic surgery success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of repigmentation of vitiligo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: DLQI score after operation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: knowledge change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: changes to clinical practice
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: increased use of research information
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Development of OAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c < 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c < or = 6.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined hypoglycemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Resolution of renal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in abdominal pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in joint pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: door to balloon time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean NAPQI formation clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: β2M clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Post-dialysis β2M serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Aqueous flare values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported levels of physical and/or sexual IPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported ability to control hostility and manage conflict
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participation in gendered household tasks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Stroke risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to glottic visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of glottic advances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Impairment on tasks of psychomotor speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impaired functioning in verbal memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic and metabolic stresses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of no longer being depressed (PHQ-9 score < 10) at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Between-group difference in PHQ-9 scores at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in anxiety scores over the trial period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of CIN 2+
Endpoint domain: Mortality/survival
Primary endpoint: Inhibition of P2Y(12) function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of enteric bacteria and yeasts in root-filled teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Antimicrobial effect of IKI treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Convergent validity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily CS over the pollen period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scleroderma HAQ disability index changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: United Kingdom functional score changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean PSQI score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sleep rate
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Hypnotic-taking frequency
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: WOMAC index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MBL after six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MBL after one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to SSRI antidepressants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage-saturated-fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for supplemental propofol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PsARC response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in skin lesions and disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in use of ankle radiography
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time spent in the emergency department
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Medical charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: serum and red blood cell folate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cognitive and depressive status test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of coping skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: logMAR vision improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of PEGA compared to PEG
Endpoint domain: Adverse events/effects
Primary endpoint: N-terminal pro-B type natriuretic peptide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correct thrombolysis eligibility decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intravenous rt-PA usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-thrombolysis intracranial hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Time until first oxycodone use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of SVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for positive inotropic support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: treatment failure rate due to intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of infants requiring sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usable information regarding macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in diagnosis of MT and ML
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAE symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of myomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean increase in myoma volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: plasma [NO2‐] levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Physical Well Being
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in Functional Well Being
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement in Trial Outcome Index scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reactive hyperemia response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Serum n‐3 PUFA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of inflammatory markers (lymphocyte, monocyte, TNF‐α, IL‐6, IL‐1β)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of nephrotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Risk of antibiotic failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interval cancer rate
Endpoint domain: Mortality/survival
Primary endpoint: MRI cancer-detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bone mineral density (BMD) gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new vertebral and nonvertebral fractures
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of positive urine cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maintenance of remission in ulcerative colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of arm numbness during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acetaminophen consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: percentage of patients who achieved complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients who experienced biochemical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of respiratory potentially allergic adverse events (PAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of digestive potentially allergic adverse events (PAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of positive skin prick test (SPT) to cow's milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median time to maximum observed plasma concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of total nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients achieving 90% clearance of nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: composite clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major amputation rate
Endpoint domain: Adverse events/effects
Primary endpoint: ongoing/recurrent ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Survival without recurrent mitral regurgitation
Endpoint domain: Mortality/survival
Primary endpoint: percentage of flow‐mediated dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Hospitalization for cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hospitalization for coronary events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean 2-point difference in the Lequesne index area-under-the-curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage time gastric pH below 4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Microbial retention efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRES scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall satisfaction with postoperative care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall crude survival
Endpoint domain: Mortality/survival
Primary endpoint: Loco-regional tumour control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement on objective measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rise in blood pressure
Endpoint domain: Adverse events/effects
Primary endpoint: restlessness
Endpoint domain: Adverse events/effects
Primary endpoint: Vigorous physical activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset-time for motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of carotid artery stenosis (CAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean mPPPASI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mPPPASI 75 achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of systolic pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in breathlessness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retraining sitting symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: YOS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25(OH)VitD values ≥20ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25(OH)VitD values ≥30ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum 25(OH)VitD levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median total SAFT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RV failure incidence
Endpoint domain: Mortality/survival
Primary endpoint: functional complications (speaking and chewing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: late TCC malfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thrombosis-free TCC survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean CD4+ T‐lymphocyte percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma HIV‐RNA log
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Stomach cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: Willingness to be contacted about intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost per additional survey completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Expression of HLA-DR and Fc receptors on monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ΔPVHb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic glucose and energy metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Day 28 PCR-adjusted ACPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting α‐HB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BCAA increments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma non‐esterified fatty acids (NEFA) increments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean consumption of fruit and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hsCRP levels post-PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of improvement of subjective symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of cosmetic xerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: menstrual-like cramping
Endpoint domain: Adverse events/effects
Primary endpoint: use of antidiarrheal agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: perineal irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: odds reduction in primary end point with early invasive strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants with HI titres ≥1:40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in HCV‐RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident Major Cardiovascular Events (MCVE) risk
Endpoint domain: Mortality/survival
Primary endpoint: FGF21 levels at 1-year post-randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motivational Interviewing Treatment Integrity scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MI counseling knowledge, skills and confidence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Closure of all fistulas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median length of time during which the fistulas remained closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mucosal healing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of Orthostatic Hypotension (OH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic Blood Pressure (SBP) maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary BOM levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of developing T2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of developing CVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in SPARCC scores for spinal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to site the ISC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery of motor and sensory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes